A Comprehensive Review of Allosteric KRAS-G12C Inhibitors: Structure, Mechanism of Action, Challenges, and Therapeutic Development Perspectives
Gene, Cell and Tissue · 30.04.2026 · 13 (2)
DOI: 10.5812/gct-172151 ↗Kurz gefasst
Fachartikel in der Zeitschrift Gene, Cell and Tissue, online erschienen am 30.04.2026. Verfasst von Amirhossien Alamdarifar und 1 weiteren Autor:innen. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Context
KRAS-G12C has emerged as a clinically tractable oncogenic RAS mutation, establishing a new paradigm for allele-specific precision oncology. Covalent allosteric inhibitors, including sotorasib and adagrasib, have demonstrated meaningful clinical activity, particularly in advanced non-small cell lung cancer. However, intrinsic and acquired resistance limit their therapeutic efficacy. This review classifies key KRAS-G12C inhibitors according to their chemical scaffolds and binding modes, examines molecular and clinical mechanisms of resistance, and discusses emerging therapeutic strategies and future directions. Evidence Acquisition: Searches were conducted in Google Scholar and the National Center for Biotechnology Information, including PubMed where applicable. Reference lists of relevant articles were also screened to identify additional publications.
Results
Current covalent KRAS-G12C inhibitors bind to the inducible switch II pocket and irreversibly stabilize the inactive guanosine diphosphate (GDP)-bound conformation, thereby suppressing downstream signaling. Resistance involves heterogeneous mechanisms, including secondary KRAS alterations, activation of bypass receptor tyrosine kinase pathways, reactivation of RAS–ERK and phosphatidylinositol 3-kinase (PI3K)–AKT signaling, and adaptive remodeling of the tumor microenvironment. Emerging approaches include next-generation covalent and noncovalent KRAS-G12C inhibitors, pan-KRAS and pan-RAS strategies, and inhibitors of Son of Sevenless homolog 1 (SOS1) and Src homology 2 domain-containing phosphatase 2 (SHP2). Rational combination regimens aim to improve therapeutic responses by simultaneously targeting upstream, downstream, and parallel survival pathways.
Conclusions
KRAS-G12C inhibition represents a major advance in precision oncology, although resistance remains a central challenge. Further progress will depend on integrating improved inhibitor design with a deeper understanding of resistance biology and rational combination strategies to enhance the depth and durability of clinical responses.
Zitieren
APA
Alamdarifar, A., & Kia, S. (2026). A Comprehensive Review of Allosteric KRAS-G12C Inhibitors: Structure, Mechanism of Action, Challenges, and Therapeutic Development Perspectives. Gene, Cell and Tissue, 13(2). https://doi.org/10.5812/gct-172151
Vancouver
Alamdarifar A, Kia S. A Comprehensive Review of Allosteric KRAS-G12C Inhibitors: Structure, Mechanism of Action, Challenges, and Therapeutic Development Perspectives. Gene, Cell and Tissue. 2026;13(2). doi:10.5812/gct-172151
BibTeX
@article{Alamdarifar2026,
author = {Alamdarifar, Amirhossien and Kia, Solmaz},
title = {A Comprehensive Review of Allosteric KRAS-G12C Inhibitors: Structure, Mechanism of Action, Challenges, and Therapeutic Development Perspectives},
journal = {Gene, Cell and Tissue},
year = {2026},
volume = {13},
number = {2},
doi = {10.5812/gct-172151}
}
EUVIMED